ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced completion of enrollment in its Phase 2 clinical trial evaluating ANKTIVA® (nogapendekin alfa inbakicept-pmln) ...
Oncology Nurse Advisor

Rates of Bilateral Mastectomy Have Doubled in Low-Risk HR+ Ductal Carcinoma In Situ

In this study, researchers aimed to examine trends in nonsurgical management and other treatment modalities in low-risk, HR-positive DCIS.
PharmiWeb

ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Glo…

ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe ...
Pharmabiz

Daiichi Sankyo submits Enhertu sNDA in Japan as adjuvant therapy for patients with HER2 positive early breast cancer

Daiichi Sankyo submits Enhertu sNDA in Japan as adjuvant therapy for patients with HER2 positive early breast cancer: Tokyo Monday, March 2, 2026, 12:00 Hrs [IST] Daiichi Sankyo h ...

ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Biopharma and ...

Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its core product APL-1702 (trade name: CEVIRA®), has ...

TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...
The Cardiology Advisor

GLP1-RA Therapy May Improve OS, But Not DFS, in Breast Cancer Survivors

GLP1-RA use may be linked to improved overall survival, but not improved disease-free survival, in breast cancer survivors, researchers report.
InvestorsHub on MSN

Protara reports encouraging phase 2 results for TARA-002 in bladder cancer study

Protara Therapeutics (NASDAQ:TARA) on February 23, 2026, announced updated interim data from its ongoing Phase 2 ADVANCED-2 trial evaluating intravesical TARA-002 in patients with high-risk non-muscle ...

Doctors stress early cancer screening to detect stage zero disease sooner

Routine tests like mammography, pap smear and colonoscopy can enable timely treatment and better survival outcomes if done at recommended intervals ...
Oncology Nurse Advisor

Mohs Micrographic Surgery Rates Have Increased in Patients of All Skin Colors

Researchers examined trends in the utilization of various surgical procedures for skin cancer stratified by patient skin color.

ImmunityBio Expands Access to ANKTIVA(R) in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch

ImmunityBio partner Accord Healthcare to deploy an 85-person sales force to drive ANKTIVA commercialization across 30 countries -- Dublin-based subsidiary to support ImmunityBio's distribution and ...